Overall rank by patents
#23,986
of 50,000 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 8 technology areas, recorded in grant years 2018–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME).
The verdict
According to USPTO PatentsView, Biostage ranks #23,986 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 8 technology areas.
USPTO PatentsView assignee plate
Corpus R23986 · US Corporation #23,986 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL
Nearest grant-volume peer: Besing Technology (shenzhen) Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Biostage · this assignee
35 score
3D Lighting Innovati… · lowest
7 score
What this shows Biostage's Innovation Score is 34.5/100 (top 52% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Biostage, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 63.6% of grants classified under C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2020. By volume, Biostage sits between Besing Technology (shenzhen) Co., Ltd. and Black Gold Coin, Inc..
Biostage, Inc. shows 5 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Besing Technology (Shenzhen) Co., Ltd.
11 patents
BiOWiSH Technologies, Inc.
11 patents
BioDerm, Inc.
11 patents
Biolife, L.L.C.
11 patents
Birad—Research & Development Company Ltd.
11 patents
Bird Technologies Group Inc.
11 patents
Birmingham Technologies, Inc.
11 patents
Black Gold Coin, Inc.
11 patents
Biostage, Inc.
11 patents
What this shows Biostage holds 11 patents at rank #24,007, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #24,007 in granted patent volume.
Other assignees with the most granted patents in Biostage's primary technology class.
Biostage's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 Top 52% higher than 48% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 18.2% |
| 2019 | 3 | 27.3% |
| 2020 | 1 | 9.1% |
| 2022 | 5 | 45.5% |
Top 8 of 8 technology areas
Overall rank by patents
#23,986
of 50,000 tracked assignees
34.5 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.